The glucose-lowering potential of exenatide delivered orally via goblet cell- targeting nanoparticles

Pharmaceutical Research

Volumn 32, Issue 3, 2015, Pages 1017-1027

  Li, Xiang ^a,b   Wang, Chenhui ^a   Liang, Rongcai ^a,b,c   Sun, Fengying ^a   Shi, Yanan ^a,b   Wang, Aiping ^b,c   Liu, Wanhui ^b,c   Sun, Kaoxiang ^b,c   Li, Youxin ^a,b,c  

^a JILIN UNIVERSITY   (China)

^b State Key Laboratory of Long acting and Targeting Drug Delivery System   (China)

^c YANTAI UNIVERSITY   (China)

Author keywords

CSK peptide modified chitosan; exenatide; goblet cell targeting nanoparticles; in vivo image system; oral delivery system

Indexed keywords

CHITOSAN NANOPARTICLE; EXENDIN 4; FLUORESCENT DYE; ANTIDIABETIC AGENT; CHITOSAN; DRUG CARRIER; GLUCOSE BLOOD LEVEL; NANOPARTICLE; OLIGOPEPTIDE; PEPTIDE; VENOM;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDIABETIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CACO 2 CELL LINE; COCULTURE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; ESOPHAGUS; FLUORESCENCE IMAGING; GOBLET CELL; HT 29 CELL LINE; IN VIVO STUDY; MALE; MOUSE; NEAR INFRARED SPECTROSCOPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; RAT; SMALL INTESTINE; STOMACH; ANIMAL; BIOTRANSFORMATION; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; HUMAN; INTESTINE ABSORPTION; MEDICINAL CHEMISTRY; METABOLISM; NANOMEDICINE; ORAL DRUG ADMINISTRATION; PERMEABILITY; PHARMACEUTICS; PROCEDURES; SPRAGUE DAWLEY RAT; TISSUE DISTRIBUTION;

ADMINISTRATION, ORAL; ANIMALS; BIOTRANSFORMATION; BLOOD GLUCOSE; CACO-2 CELLS; CELL SURVIVAL; CHEMISTRY, PHARMACEUTICAL; CHITOSAN; DRUG CARRIERS; GOBLET CELLS; HT29 CELLS; HUMANS; HYPOGLYCEMIC AGENTS; INTESTINAL ABSORPTION; MALE; NANOMEDICINE; NANOPARTICLES; OLIGOPEPTIDES; PEPTIDES; PERMEABILITY; RATS, SPRAGUE-DAWLEY; TECHNOLOGY, PHARMACEUTICAL; TISSUE DISTRIBUTION; VENOMS;

EID: 84922983749     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-014-1513-1     Document Type: Article

References (23)

1. Gedulin BR, Smith PA, Jodka CM, Chen K, Bhavsar S, Nielsen LL, et al. Pharmacokinetics and pharmacodynamics of exenatide following alternate routes of administration. Int J Pharm. 2008;356:231-8.
2. Eng J, Kleinman WA, Singh L, Singh G, Raufman JP. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem. 1992;267:7402-5.
3. Goke R, Fehmann HC, Linn T, Schmidt H, Krause M, Eng J, et al. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. J Biol Chem. 1993;268:19650-5.
4. Hamman JH, Enslin GM, Kotze AF. Oral delivery of peptide drugs: barriers and developments. BioDrugs. 2005;19:165-77.
5. Jin Y, Song Y, Zhu X, Zhou D, Chen C, Zhang Z, et al. Goblet cell-targeting nanoparticles for oral insulin delivery and the influence of mucus on insulin transport. Biomaterials. 2012;33:1573-82.
6. Felt O, Buri P, Gurny R. Chitosan: a unique polysaccharide for drug delivery. Drug Dev Ind Pharm. 1998;24:979-93.
7. Zhao J, Fan X, Zhang Q, Sun F, Li X, Xiong C, Zhang C, Fan H. Chitosan-plasmid DNA nanoparticles encoding small hairpin RNA targeting MMP-3 and -13 to inhibit the expression of dedifferentiation related genes in expanded chondrocytes. J Biomed Mater Res A. 2013.
8. Sonaje K, Lin K-J, Wey S-P, Lin C-K, Yeh T-H, Nguyen H-N, et al. Biodistribution, pharmacodynamics and pharmacokinetics of insulin analogues in a rat model: Oral delivery using pH-Responsive nanoparticles vs. subcutaneous injection. Biomaterials. 2010;31:6849-58.
9. Dash M, Chiellini F, Ottenbrite RM, Chiellini E. Chitosan - A versatile semi-synthetic polymer in biomedical applications. Prog Polym Sci. 2011;36:981-1014.
10. Shiraishi S, Imai T, Otagiri M. Controlled release of indomethacin by chitosan-polyelectrolyte complex: optimization and in vivo/in vitro evaluation. J Control Release. 1993;25:217-25.
11. Jin C-H, Chae SY, Son S, Kim TH, Um KA, Youn YS, et al. A new orally available glucagon-like peptide-1 receptor agonist, biotinylated exendin-4, displays improved hypoglycemic effects in db/db mice. J Control Release. 2009;133:172-7.
12. Roger E, Lagarce F, Garcion E, Benoit J-P. Biopharmaceutical parameters to consider in order to alter the fate of nanocarriers after oral delivery. Nanomedicine (London, U K). 2010;5:287-306.
13. Kang SK, Woo JH, Kim MK, Woo SS, Choi JH, Lee HG, et al. Identification of a peptide sequence that improves transport of macromolecules across the intestinal mucosal barrier targeting goblet cells. J Biotechnol. 2008;135:210-6.
14. Gupta V, Doshi N, Mitragotri S. Permeation of insulin, calcitonin and exenatide across Caco-2 monolayers: measurement using a rapid, 3-day system. PLoS One. 2013;8:e57136.
15. Wangand Q, Brubaker PL. Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice. Diabetologia. 2002;45:1263-73.
16. Nguyen HN, Wey SP, Juang JH, Sonaje K, Ho YC, Chuang EY, et al. The glucose-lowering potential of exendin-4 orally delivered via a pH-sensitive nanoparticle vehicle and effects on subsequent insulin secretion in vivo. Biomaterials. 2011;32:2673-82.
17. Hilgendorf C, Spahn-Langguth H, Regardh CG, Lipka E, Amidon GL, Langguth P. Caco-2 versus Caco-2/HT29-MTX co-cultured cell lines: permeabilities via diffusion, inside- and outside-directed carrier-mediated transport. J Pharm Sci. 2000;89:63-75.
18. Behrens I, Pena AI, Alonso MJ, Kissel T. Comparative uptake studies of bioadhesive and non-bioadhesive nanoparticles in human intestinal cell lines and rats: the effect of mucus on particle adsorption and transport. Pharm Res. 2002;19:1185-93.
19. Schipper NG, Varum KM, Stenberg P, Ocklind G, Lennernas H, Artursson P. Chitosans as absorption enhancers of poorly absorbable drugs. 3: influence of mucus on absorption enhancement. Eur J Pharm Sci. 1999;8:335-43.
20. Deliolanisand NC, Ntziachristos V. Fluorescence molecular tomography of brain tumors in mice. Cold Spring Harb Protocol. 2013;2013:438-43.
21. Xiang Y, Liang L, Wang X, Wang J, Zhang X, Zhang Q. Chloride channel-mediated brain glioma targeting of chlorotoxin-modified doxorubicine-loaded liposomes. J Control Release. 2011;152:402-10.
22. Gallwitz B. The evolving place of incretin-based therapies in type 2 diabetes. Pediatr Nephrol. 2010;25:1207-17.
23. Nielsen LL, Young AA, Parkes DG. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept. 2004;117:77-88.